Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Puma Biotechnology reports revenue growth and strategic advancements in oncology

Puma Biotechnology's Q4 2022 performance reflects revenue growth, cost reductions, and a focus on improving NERLYNX sales.
The company faces challenges in addressing financial losses, FDA trial requirements, and optimizing commercial strategies.
Opportunities in advancing clinical programs, FDA discussions, and market expansion present avenues for future growth and innovation.
Overall, Puma's strategic focus on revenue enhancement, cost control, and innovative treatments positions them for continued progress in the oncology market.

Puma Biotechnology reports solid Q1 earnings, eyes oncology expansion

Puma Biotechnology's Q1 2023 performance driven by strong NERLYNX sales and revenue growth.
Focus on in-licensing alisertib and optimizing expenses for sustained profitability.
Challenges include competition, patent issues, and trial enrollment hurdles.
Opportunities lie in expanding alisertib's indications and in-licensing assets for growth.

Puma Biotechnology reports revenue growth and advances in clinical trials

Puma Biotechnology's Q2 2023 performance showcased revenue growth driven by NERLYNX sales and promising results from alisertib trials. Despite challenges in NERLYNX prescriptions and FDA expectations, strategic initiatives aim to boost sales and advance clinical development. Opportunities in commercial strategies and clinical trials present avenues for future growth.

Puma Biotechnology reports solid Q3 earnings amidst sales challenges

Puma Biotechnology reported solid financial performance in Q3 2023 despite challenges in NERLYNX sales.
The company's focus on improving sales, pursuing clinical trials, and reducing expenses positions it for future growth.
Opportunities lie in enhancing NERLYNX sales, diversifying the product portfolio, and achieving clinical milestones.
Navigating challenges in sales and portfolio diversification while capitalizing on opportunities will be key for Puma's success.

Puma Biotechnology reports stable Q4 earnings amidst prescription challenges

Puma Biotechnology's Q4 2023 performance reflects solid revenue figures and a focus on profitability despite prescription declines.
The company's strengths lie in its innovative trials, commercial strategies, and optimistic revenue projections for the future.
Challenges include prescription decreases and inventory impacts, while opportunities exist in diversification, engagement enhancement, and market differentiation.

Puma Biotechnology reports revenue growth and strategic expansion plans

Puma Biotechnology's Q1 2024 performance reflects revenue growth and strategic initiatives to drive sales and enhance profitability.
While facing challenges in maintaining NERLYNX sales and managing expenses, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, financial stability, and market expansion, Puma is poised for continued growth and success in the biotechnology sector.
Investors should monitor Puma's progress in clinical trials, revenue diversification, and cost management for insights into its future performance.

Puma Biotechnology reports strong revenue, eyes product approvals for growth

Puma Biotechnology's Q2 2024 performance reflects solid revenue generation and strategic investment in innovation.
While facing challenges such as declining new prescriptions and a net loss, the company maintains a focus on cost management.
Opportunities lie in product approvals, revenue growth, and leveraging financial stability for future growth initiatives.
Overall, Puma's financial outlook remains positive, supported by a strong product pipeline and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

An analyst downgrade and a departing executive make for a bad day.

Here's Why Puma Biotechnology Tumbled Today

The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.

Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx

Nerlynx's Q1 numbers were disappointing, and the market punished the stock immensely. I believe the market took it too far and has discounted the stock following an encouraging Q2.

Puma Biotechnology: A Speculative Investment At A Discount

Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.

Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?

The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.

Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report?

Puma Biotechnology Inc. (NASDAQ: PBYI) shares jumped early Wednesday after the announcement that the U.S. Food and Drug Administration (FDA) provided an update on the company’s breast cancer treatment.

What This Recent FDA Move Could Mean for Breast Cancer Patients With Brain Metastases

Puma Biotechnology Inc (NASDAQ: PBYI) shares advanced in premarket trading Wednesday on the back of an announcement concerning its breast cancer drug Nerlynx before falling after the market open.

Puma's Breast Cancer Drug Accorded Orphan Drug Designation For Brain Metastases

Puma Biotechnology Inc. PBYI, -2.98% shares rallied in the extended session Tuesday after the drug developer said the Food and Drug Administration granted its cancer treatment a special designation.

Puma Biotech stock surges on FDA cancer drug designation

Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels.

Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2019 Results - Earnings Call Transcript

Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?

Here's Why Puma Biotechnology Fell 24.1% in July

Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotech (PBYI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Implied Volatility Surging for Puma Biotech (PBYI) Stock Options

Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.

Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx

Tallgrass Energy LP - Ordinary Shares - Class A

XPO Logistics

The market's shortsightedness has it missing the long-term upside at this biotech, logistics specialist, and pipeline company.

Wall Street Has Given Up on These 3 Stocks; and That's a Huge Mistake

Puma Biotechnology stock has dropped back to investable levels as the Q1 2019 sales disappointed and the out-licensing deals did not impress investors.

Puma Biotech: Wounded Predator Ready To Jump Back

Puma Biotech (PBYI) Down 53.9% Since Last Earnings Report: Can It Rebound?

The most significant potential concern for the company's lone drug product arose.

Here's Why Puma Biotechnology Tumbled 53.9% in May

1Q19 Nerlynx net sales came in much lower than expected, due mainly to the increase in discontinuations.

Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy

A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.

Investors Are Right to Worry About Puma Biotechnology

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2019 Results - Earnings Call Transcript

There are risks to having only one marketed drug product.

Here's Why Puma Biotechnology Fell as Much as 40.7% Today

Puma stock was hammered Friday after sales of breast cancer treatment Nerlynx lagged the Street by north of $20 million despite a first-quarter price hike. Puma also cut its 2019 outlook.

Biotech Hammered On 'Shockingly Poor' Report For Breast Cancer Drug

Shares of small-cap oncology biotech Puma Biotechnology Inc. are sinking to their lowest level since November following the release of its first-quarter results.

News for Puma Biotechnology Stock (PBYI)